

# Koichi Yanaba

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4258388/publications.pdf>

Version: 2024-02-01

72  
papers

6,502  
citations

201674

27  
h-index

79698

73  
g-index

73  
all docs

73  
docs citations

73  
times ranked

7411  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibitory role of interleukin-10 in the cutaneous reverse Arthus reaction. <i>Journal of Dermatology</i> , 2021, 48, 219-222.	1.2	2
2	Adult-onset generalized morphea associated with osteomyelitis. <i>Journal of Dermatology</i> , 2020, 47, e446-e447.	1.2	1
3	Usefulness of dual-energy computed tomography for the evaluation of psoriatic arthritis accompanied by knee osteoarthritis. <i>Journal of Dermatology</i> , 2019, 46, e30-e32.	1.2	1
4	Clinical characteristics of anti-Ro52 <sup>±</sup> and anti-Ro52 <sup>2</sup> antibodies in dermatomyositis/polymyositis. <i>Journal of Dermatological Science</i> , 2019, 96, 50-52.	1.9	1
5	Anti-SAE Antibody-Positive Dermatomyositis in a Japanese Patient. <i>Journal of Clinical Rheumatology</i> , 2019, 25, e115-e116.	0.9	7
6	Hearing loss caused by discoid lupus erythematosus of the ear canal successfully treated with hydroxychloroquine. <i>Journal of Dermatology</i> , 2019, 46, e313-e314.	1.2	1
7	Relationship between the Degrees of Itch and Serum Lipocalin-2 Levels in Patients with Psoriasis. <i>Journal of Immunology Research</i> , 2019, 2019, 1-8.	2.2	26
8	Serum KL-6 levels in Japanese patients with psoriasis treated with secukinumab. <i>Journal of Dermatology</i> , 2019, 46, e115-e116.	1.2	4
9	Expression of T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain on CD4 <sup>+</sup> T cells in patients with atopic dermatitis. <i>Journal of Dermatology</i> , 2019, 46, 37-42.	1.2	13
10	IL-10 <sup>+</sup> Producing Regulatory B Cells Are Decreased in Patients with Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2019, 139, 475-478.	0.7	26
11	Exacerbation of atopic dermatitis symptoms by ustekinumab in psoriatic patients with elevated serum immunoglobulin E levels: Report of two cases. <i>Journal of Dermatology</i> , 2018, 45, 732-734.	1.2	24
12	Clinical Significance of Serum Galectin-9 and Soluble CD155 Levels in Patients with Systemic Sclerosis. <i>Journal of Immunology Research</i> , 2018, 2018, 1-5.	2.2	14
13	Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: A longitudinal observational study. <i>Journal of Dermatology</i> , 2018, 45, 1425-1433.	1.2	22
14	Anti-transcription intermediary factor-1 <sup>±/2</sup> antibody-positive dermatomyositis associated with multiple panniculitis lesions. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1831-1834.	1.9	4
15	Anti-PM/Scl antibody-positive dermatomyositis in a Japanese patient: a case report and review of the literature. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 2186-2189.	1.9	8
16	Switching of biologics in psoriasis: Reasons and results. <i>Journal of Dermatology</i> , 2017, 44, 1015-1019.	1.2	38
17	Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics. <i>Journal of Dermatology</i> , 2017, 44, 1112-1121.	1.2	73
18	Biologic treatments for elderly patients with psoriasis. <i>Journal of Dermatology</i> , 2017, 44, 1020-1023.	1.2	27

#	ARTICLE	IF	CITATIONS
19	Superiority of magnetic resonance imaging over conventional radiography in the early diagnosis of psoriatic arthritis. <i>Journal of Dermatology</i> , 2017, 44, e232-e233.	1.2	2
20	Impact of anti-tumor necrosis factor- $\alpha$ agents on serum levels of KL-6 and surfactant protein-D in patients with psoriasis. <i>Journal of Dermatology</i> , 2017, 44, 1063-1066.	1.2	11
21	Usefulness of dual-energy computed tomography for the evaluation of early-stage psoriatic arthritis only accompanied by nail psoriasis. <i>Journal of Dermatology</i> , 2017, 44, e326-e327.	1.2	2
22	New onset or transition of disease state of psoriatic arthritis during treatment with ustekinumab: A single-center retrospective study. <i>Journal of Dermatology</i> , 2017, 44, 1380-1384.	1.2	9
23	Clinical significance of serum soluble T-cell immunoglobulin and mucin domain 3 levels in systemic sclerosis: Association with disease severity. <i>Journal of Dermatology</i> , 2017, 44, 194-197.	1.2	14
24	Septic arthritis caused by <i>Mycobacterium marinum</i> infection. <i>Journal of Dermatology</i> , 2017, 44, 1179-1180.	1.2	2
25	Serum C-reactive protein levels in Japanese patients with psoriasis and psoriatic arthritis: Long-term differential effects of biologics. <i>Journal of Dermatology</i> , 2016, 43, 779-784.	1.2	33
26	Circulating galectin-1 concentrations in systemic sclerosis: potential contribution to digital vasculopathy. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 622-627.	1.9	15
27	Cutaneous plasmacytosis successfully treated with narrowband ultraviolet B irradiation therapy. <i>Journal of Dermatology</i> , 2016, 43, 229-230.	1.2	6
28	Antinuclear antibody formation following administration of anti-tumor necrosis factor agents in Japanese patients with psoriasis. <i>Journal of Dermatology</i> , 2016, 43, 443-444.	1.2	4
29	Serum levels of soluble programmed death-1 and programmed death ligand-1 in systemic sclerosis: Association with extent of skin sclerosis. <i>Journal of Dermatology</i> , 2016, 43, 954-957.	1.2	34
30	Nodular fasciitis on the face. <i>Journal of Dermatology</i> , 2016, 43, 1235-1236.	1.2	7
31	Recurrent neutrophilic dermatosis of the face: A report of two cases and review of the published work. <i>Journal of Dermatology</i> , 2016, 43, 811-814.	1.2	2
32	Strategy for treatment of fibrosis in systemic sclerosis: Present and future. <i>Journal of Dermatology</i> , 2016, 43, 46-55.	1.2	34
33	IL-10-producing regulatory B cells are decreased in patients with psoriasis. <i>Journal of Dermatological Science</i> , 2016, 81, 93-100.	1.9	54
34	Effect of ambrisentan on peripheral circulation in patients with systemic sclerosis. <i>Modern Rheumatology</i> , 2016, 26, 454-457.	1.8	1
35	Adalimumab markedly improves enthesitis in patients with psoriatic arthritis: Evaluation with a magnetic resonance imaging scoring system. <i>Journal of Dermatology</i> , 2015, 42, 1153-1159.	1.2	10
36	Four cases of Japanese patients with psoriatic arthritis in whom effective treatments by anti-tumor necrosis factor- $\alpha$ drugs were evaluated by magnetic resonance imaging together with improvement of skin lesions. <i>Journal of Dermatology</i> , 2015, 42, 49-55.	1.2	4

#	ARTICLE	IF	CITATIONS
37	Infliximab and adalimumab, unlike ustekinumab, increase serum KL-6 levels in Japanese patients with psoriasis. <i>Journal of Dermatology</i> , 2015, 42, 828-829.	1.2	10
38	Impact of obesity on the efficacy of ustekinumab in Japanese patients with psoriasis: a retrospective cohort study of 111 patients. <i>Archives of Dermatological Research</i> , 2014, 306, 921-925.	1.9	24
39	Successful experience of rituximab therapy for systemic sclerosis-associated interstitial lung disease with concomitant systemic lupus erythematosus. <i>Journal of Dermatology</i> , 2014, 41, 418-420.	1.2	23
40	In-Stent Restenosis Exacerbated by Drug-Induced Severe Eosinophilia after Second-Generation Drug-Eluting Stent Implantation. <i>American Journal of Case Reports</i> , 2014, 15, 397-400.	0.8	8
41	CD19 Expression in B Cells Regulates Atopic Dermatitis in a Mouse Model. <i>American Journal of Pathology</i> , 2013, 182, 2214-2222.	3.8	28
42	Increased production of soluble inducible costimulator in patients with diffuse cutaneous systemic sclerosis. <i>Archives of Dermatological Research</i> , 2013, 305, 17-23.	1.9	20
43	Increased circulating fibrinogen-like protein 2 in patients with systemic sclerosis. <i>Clinical Rheumatology</i> , 2013, 32, 43-47.	2.2	10
44	Increased circulating soluble vascular adhesion protein-1 levels in systemic sclerosis: association with lower frequency and severity of interstitial lung disease. <i>International Journal of Rheumatic Diseases</i> , 2013, 16, 442-447.	1.9	4
45	Regulatory B cells suppress imiquimod-induced, psoriasis-like skin inflammation. <i>Journal of Leukocyte Biology</i> , 2013, 94, 563-573.	3.3	81
46	Clinical significance of monitoring serum adiponectin levels during intravenous pulse cyclophosphamide therapy in interstitial lung disease associated with systemic sclerosis. <i>Modern Rheumatology</i> , 2013, 23, 323-329.	1.8	20
47	Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity. <i>Modern Rheumatology</i> , 2012, 22, 668-675.	1.8	37
48	A possible contribution of elevated serum clusterin levels to the inhibition of digital ulcers and pulmonary arterial hypertension in systemic sclerosis. <i>Archives of Dermatological Research</i> , 2012, 304, 459-463.	1.9	7
49	Proteasome Inhibitor Bortezomib Ameliorates Intestinal Injury in Mice. <i>PLoS ONE</i> , 2012, 7, e34587.	2.5	12
50	Clinical significance of circulating platelet-activating factor acetylhydrolase levels in systemic sclerosis. <i>Archives of Dermatological Research</i> , 2012, 304, 203-208.	1.9	10
51	Increased serum soluble CD147 levels in patients with systemic sclerosis: association with scleroderma renal crisis. <i>Clinical Rheumatology</i> , 2012, 31, 835-839.	2.2	24
52	Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity. <i>Modern Rheumatology</i> , 2012, 22, 668-675.	1.8	13
53	IL-10-Producing Regulatory B10 Cells Inhibit Intestinal Injury in a Mouse Model. <i>American Journal of Pathology</i> , 2011, 178, 735-743.	3.8	172
54	Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. <i>Blood</i> , 2011, 117, 530-541.	1.4	969

#	ARTICLE	IF	CITATIONS
55	Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. <i>Clinical Rheumatology</i> , 2011, 30, 825-830.	2.2	116
56	Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. <i>Arthritis and Rheumatism</i> , 2011, 63, 3575-3585.	6.7	81
57	Serum Interleukin 9 Levels Are Increased in Patients with Systemic Sclerosis: Association with Lower Frequency and Severity of Pulmonary Fibrosis. <i>Journal of Rheumatology</i> , 2011, 38, 2193-2197.	2.0	46
58	Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2010, 62, 2476-2487.	6.7	118
59	The Development and Function of Regulatory B Cells Expressing IL-10 (B10 Cells) Requires Antigen Receptor Diversity and TLR Signals. <i>Journal of Immunology</i> , 2009, 182, 7459-7472.	0.8	443
60	CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model. <i>Arthritis and Rheumatism</i> , 2008, 58, 3574-3584.	6.7	73
61	B-lymphocyte contributions to human autoimmune disease. <i>Immunological Reviews</i> , 2008, 223, 284-299.	6.0	306
62	Regulatory B cells as inhibitors of immune responses and inflammation. <i>Immunological Reviews</i> , 2008, 224, 201-214.	6.0	400
63	A Regulatory B Cell Subset with a Unique CD1dhiCD5+ Phenotype Controls T Cell-Dependent Inflammatory Responses. <i>Immunity</i> , 2008, 28, 639-650.	14.3	1,127
64	Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. <i>Journal of Clinical Investigation</i> , 2008, 118, 3420-30.	8.2	762
65	B Cell Depletion Delays Collagen-Induced Arthritis in Mice: Arthritis Induction Requires Synergy between Humoral and Cell-Mediated Immunity. <i>Journal of Immunology</i> , 2007, 179, 1369-1380.	0.8	128
66	Intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 cooperatively contribute to the cutaneous Arthus reaction. <i>Journal of Leukocyte Biology</i> , 2007, 81, 1197-1204.	3.3	16
67	Therapeutic B cell depletion impairs adaptive and autoreactive CD4 <sup>+</sup> T cell activation in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 20878-20883.	7.1	282
68	B-Lymphocyte Depletion Reduces Skin Fibrosis and Autoimmunity in the Tight-Skin Mouse Model for Systemic Sclerosis. <i>American Journal of Pathology</i> , 2006, 169, 954-966.	3.8	195
69	Elevated serum BAFF levels in patients with systemic sclerosis: Enhanced BAFF signaling in systemic sclerosis B lymphocytes. <i>Arthritis and Rheumatism</i> , 2006, 54, 192-201.	6.7	242
70	Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. <i>Journal of Rheumatology</i> , 2004, 31, 1112-20.	2.0	78
71	Relative Contributions of Selectins and Intercellular Adhesion Molecule-1 to Tissue Injury Induced by Immune Complex Deposition. <i>American Journal of Pathology</i> , 2003, 162, 1463-1473.	3.8	35
72	The Cutaneous Reverse Arthus Reaction Requires Intercellular Adhesion Molecule 1 and L-Selectin Expression. <i>Journal of Immunology</i> , 2002, 168, 2970-2978.	0.8	42